The transcription factor EB (TFEB) regulates the expression of target genes bearing the Coordinated Lysosomal Expression and Regulation (CLEAR) motif, thereby modulating autophagy and lysosomal biogenesis. Furthermore, TFEB can bind to the promoter of autophagy-associated genes and induce the formation of autophagosomes, autophagosome-lysosome fusion, and lysosomal cargo degradation. An increasing number of studies have shown that TFEB stimulates the intracellular clearance of pathogenic factors by enhancing autophagy and lysosomal function in multiple kidney diseases, such as cystinosis, acute kidney injury, and diabetic nephropathy. Taken together, this highlights the importance of developing novel therapeutic strategies against kidney diseases based on TFEB regulation. In this review, we present an overview of the current data on TFEB and its implication in kidney disease.

中文翻译：

---

TFEB 活性的调节及其作为肾脏疾病治疗靶点的潜力。

转录因子 EB (TFEB) 调节带有协调溶酶体表达和调节 (CLEAR) 基序的靶基因的表达，从而调节自噬和溶酶体生物合成。此外，TFEB可以与自噬相关基因的启动子结合，诱导自噬体的形成、自噬体-溶酶体融合和溶酶体货物降解。越来越多的研究表明，TFEB在多种肾脏疾病（如胱氨酸病、急性肾损伤和糖尿病肾病）中通过增强自噬和溶酶体功能来刺激细胞内致病因子的清除。总而言之，这凸显了开发基于 TFEB 调节的肾脏疾病新治疗策略的重要性。在这篇综述中，我们概述了 TFEB 的当前数据及其对肾脏疾病的影响。